Thursday broker round-up UPDATE
24th Oct 2013 09:25
Aquarius Platinum: Investec lowers target price from 48p to 42p and downgrades from hold to sell. ASOS: Citi increases target price from 5800p to 7000p reiterating its buy recommendation. BHP Billiton: Jefferies raises target price from 2350p to 2400p and keeps a buy recommendation. Clinigen: Inv
Read moreTuesday tips round-up: GlaxoSmithKline, Pace
24th Oct 2013 08:10
GlaxoSmithKline's sales in China tumbled by 60 per cent in the third quarter, the company revealed on Wednesday, halving the country's contribution to Glaxo's total quarterly pharmaceutical sales in emerging markets when compared with year-ago levels. However, this hides the fact that the firm's ope
Read moreLondon close: Stocks pull back from five-month high
23rd Oct 2013 17:01
- Miners, banks weigh on Footsie - Money-market rates spike in China - RSA up on bid speculation techMARK 2,624.47 -0.41% FTSE 100 6,674.48 -0.32% FTSE 250 15,494.97 -0.11% The FTSE 100 finished in negative territory for the first time in 10 trading sessions on Wednesday as traders took profits af
Read moreFTSE 100 movers: RSA rises amid heavy volume on bid talk
23rd Oct 2013 14:06
Chip designer ARM Holdings fell for the second straight day as investors gave a cool reaction to its third-quarter results. JPMorgan Cazenove said this morning that it sees "no reason to be building positions at this time and would take profits in the short term". A number of stocks were also trad
Read moreGSK beats Q3 earnings expectations despite missing on revenues
23rd Oct 2013 12:28
- Earnings ahead, revenues down - Strong cost control boosts results - GSK benefits on sale of Lucozade and Ribena GlaxoSmithKline beat earnings growth expectations in the third quarter by cutting back office and drug research and development costs were amplified by a lower tax rate. With turnove
Read moreLondon midday: Markets pull back from five-month high as banks fall
23rd Oct 2013 11:15
Concerns over the Chinese economy and a weak performance by banking stocks halted a nine-day winning streak for UK markets on Wednesday, as investors chose to take profits following a strong run. The FTSE 100 snapped a nine-day winning streak this morning, pulling back from Tuesday's finish of 6,69
Read moreBroker tips: Standard Life, GlaxoSmithKline, Whitbread
11th Oct 2013 11:19
JPMorgan Cazenove has reiterated its 'overweight' rating and 430p target price for insurance group Standard Life, adding the stock to its European 'Analyst Focus List'. The bank pointed out that the stock has been under pressure since the start of the week, partly due to erroneous data implying net
Read moreBroker snap: Generic competition fears ease at Glaxo, says Panmure
11th Oct 2013 09:48
GlaxoSmithKline's share price edged higher on Friday morning on hopes that generic versions of its best-selling drug Advair may not come to market until later than expected - something that Panmure Gordon believes is a reason to 'buy' the UK-listed stock. The broker highlighted comments from Teva,
Read moreFTSE 100 movers: Persimmon boosted by 'Help to Buy' confidence
10th Oct 2013 14:35
House builder Persimmon was a high riser this afternoon as optimism over the government's 'Help to Buy' scheme continues to help the stock bounce off recent lows. The share price has now gained over 10 per cent over the last two days. Whitbread shares leapt on market chatter about a potential spin-
Read moreGlaxoSmithKline applies for malaria vaccine approval in 2015
8th Oct 2013 09:23
The world's first malaria vaccine could be on the market as early as 2015, GlaxoSmithKline said after its advanced clinical trials proved encouraging. The FTSE 100 company's large-scale Phase III clinical trial showed its experimental malaria vaccine candidate helped reduce cases of the disease in
Read moreLondon close: Markets in 'wait-and-see' mode as shutdown continues
4th Oct 2013 16:46
After fluctuating between gains and losses for most of the day, the FTSE 100 finished broadly flat on Friday as stocks struggled for direction. In the absence of economic news and ongoing political uncertainty in the States, markets remain in "wait-and-see mode", according Senior Market Analyst Mic
Read moreBroker tips: Barclays, GlaxoSmithKline, Tate & Lyle
4th Oct 2013 12:24
Investec has raised its recommendation for banking group Barclays from 'add' to 'buy' and retained its 300p target price despite what is expected to be a 'lacklustre' third-quarter report on October 30th. Analyst Ian Gordon said that the upgrade is due to a combination of: passing rights issues-rel
Read moreLondon midday: UK markets lack direction as US budget impasse persists
4th Oct 2013 11:31
After a slow start, the FTSE 100 had erased losses by midday on Friday but markets remain subdued as stocks struggle for direction in the absence of economic news and ongoing political uncertainty in the States. Since the partial shutdown of the US government has extended into its fourth day, gove
Read moreBroker snap: Panmure upbeat about GSK despite negative Eli Lilly readacross
4th Oct 2013 10:46
Shares in GlaxoSmithKline (GSK) edged lower on Friday due to the possible negative readacross from US pharmaceuticals peer Eli Lilly, which warned about headwinds to its revenues in 2014. Nevertheless, Panmure Gordon maintained its upbeat stance on London-listed GSK, saying it would use any weaknes
Read moreLondon close: Stocks at one-month low on looming US shutdown
30th Sep 2013 16:36
Stocks were firmly lower on Monday as risk appetite was reduced in the face of a looming partial shutdown of the US government after a weekend of no progress in Washington. Political instability in Italy also dampened the mood today as well as disappointing economic data from China, with falls in t
Read more